Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Cytokinetics (CYTK) Stock Price & Analysis
958 Followers
CYTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.98 - $110.25
Previous Close$48.98
Volume15.41M
Average Volume (3M)2.14M
Market Cap
$5.14B
Enterprise Value$4.73B
Total Cash (Recent Filing)$614.82M
Total Debt (Recent Filing)$206.78M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 01, 2024EPS Estimate
-$1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.40
Shares Outstanding104,853,918
10 Day Avg. Volume2,903,496
30 Day Avg. Volume2,137,042
Standard Deviation0.24
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)-16.08
Price to Sales (P/S)682.04
Price to Cash Flow (P/CF)-21.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue627.85
Enterprise Value/Gross Profit627.85
Enterprise Value/Ebitda-13.31
Forecast
1Y Price Target
$90.79Price Target Upside85.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Clinical Data And Drug ProfileThe totality of the SEQUOIA data underscore afi's potential to be a compelling next-in-class cardiac myosin inhibitor for the treatment of oHCM.
Drug Potential And Market SupportRoyalty Pharma's commitment to provide $50 million for commercial launch funding of aficamten demonstrates strong support for the drug's market introduction.
Financial StabilityCytokinetics announced two significant transactions that provide a major boost to the company's finances and a clear signal to financially bolster aficamten's expected commercial launch.
Bears Say
Clinical DevelopmentResuscitating omecamtiv clinical development irritated investors, as shares traded higher after the omecamtiv CRL.
Financial GuidanceThe financial guidance indicates significant operational expenses, but the current cash balance and additional funding sources are expected to provide a cash runway for approximately two years.
Mergers And AcquisitionsDespite the financial boost, there may be added volatility with the shares as the market speculates about the potential for mergers and acquisitions.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $25.98 and its highest was $110.25 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Aug 01, 2024 which is in 69 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 08, 2024. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$1.144 by -$0.186.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -$1.11.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 104,853,920 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.33 in its last earnings report, missing expectations of -$1.144. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 38M.
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.79 (85.36% Upside)
$90.79 (85.36% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 868.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q1 2024
0:00 / 0:00
---
CYTK Stock 12 Month Forecast
Average Price Target
$90.79
▲(85.36% Upside)
Technical Analysis
Ligand Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
19/26 ratings generated profit
1 Year Average Return
+32.21%
reiterated a buy rating 5 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +32.21% per trade.
---